Complications of biological therapy for inflammatory bowel diseases

Current Opinion in Gastroenterology

Volumn 22, Issue 1, 2006, Pages 30-43

  Blonski, Wojciech ^a,b   Lichtenstein, Gary R ^a,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c 3 Ravdin Building ^*  (United States)

Author keywords

Biologic therapies; Complications; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BASILIXIMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DIPHENHYDRAMINE; ETANERCEPT; FONTOLIZUMAB; GAMMA INTERFERON ANTIBODY; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; MLN 02; MONOCLONAL ANTIBODY CH5D12; NATALIZUMAB; ONERCEPT; PARACETAMOL; PREDNISONE; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SEMAPIMOD; STEROID; THALIDOMIDE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSCESS; ANEMIA; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ARTHRALGIA; ASTHENIA; BACKACHE; BIOLOGICAL THERAPY; BLEEDING; BONE PAIN; BREAST TENDERNESS; BRONCHITIS; CATHETER INFECTION; CHILL; CLINICAL TRIAL; COLITIS; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; CORTICOSTEROID THERAPY; COUGHING; CREUTZFELDT JAKOB DISEASE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DEGENERATIVE DISEASE; DERMATITIS; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENTERITIS; ENZYME BLOOD LEVEL; EOSINOPHILIA; EPIGASTRIC PAIN; ERYTHEMA; ESOPHAGITIS; ESOPHAGUS CANCER; EVALUATION; EYE BURNING; FATIGUE; FIBRINOGEN BLOOD LEVEL; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; HYPERAMYLASEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; HYPOKALEMIA; ILEUS; IMMUNOREGULATION; INJECTION SITE BURNING; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE REACTION; INSOMNIA; INTESTINE OBSTRUCTION; KIDNEY CARCINOMA; KIDNEY COLIC; LETHARGY; LEUKOCYTE COUNT; LEUKOCYTOSIS; LEUKOPENIA; LIBIDO DISORDER; LOBAR PNEUMONIA; LOW BACK PAIN; LUNG ASPERGILLOSIS; LUPUS LIKE SYNDROME; LYMPHADENITIS; LYMPHOCYTE; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MIGRAINE; MONOCYTOSIS; MOOD DISORDER; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEURILEMOMA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NEUTROPHILIA; NOCARDIOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PAIN; PARESTHESIA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHLEBITIS; PHOTOSENSITIVE EPILEPSY; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRECANCER; PREGNANCY TERMINATION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; RIGOR; SEDATION; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SORE THROAT; SPONTANEOUS ABORTION; STOMACH PARESIS; STOMACH POLYP; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING; WARMING; XEROSTOMIA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOTHERAPY; INTESTINE MUCOSA; MALE; MAXIMUM TOLERATED DOSE; METHODOLOGY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDIES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644829107     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000196151.74819.8e     Document Type: Review

References (91)

1. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53:1366-1373. Very comprehensive review of the use of biologic compounds in IBD.
2. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002; 122:1592-1608.
3. Brown S, Abreu M. Biologic therapies in inflammatory bowel disease. Practical Gastroenterology 2005; XXIX:38-63. Very comprehensive review of the efficacy of biologies in IBD.
4. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119:1148-1157.
5. Remicade (Infliximab). Prescribing information. 2005. Malvern, PA: Centocor.
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
7. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117:761-769.
8. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
9. Hanauer SB, Reagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
10. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885. The largest trial on infliximab use in fistulizing Crohn's disease.
11. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542-553. Very interesting original paper showing that the development of antibodies to infliximab is lower in patients on maintenance treatment than in those on episodic treatment.
12. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608.
13. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002; 97:2962-2972.
14. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-1610.
15. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1-51.
16. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99:2385-2392. Very important study showing the results of exposure of infliximab during pregnancy.
17. Lichtenstein GR, Cohen R, Feagan B, et al. Safety of infliximab and other Crohn's disease therapies - updated TREAT registry data with over 10,000 patients-years of follow-up. Gastroenterology 2005; 128:W1034.
18. Rutgeerts P, Feagan B, Olson A, et al. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: ACT 1 Trial. Gastroenterology 2005; 128:A-105.
19. Sandborn W, Rachmilewitz D, Hanauer S, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 Trial. Gastroenterology 2005; 128:A-104-A-105.
20. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349:521-524.
21. Feagan B, Sandborn W, Baker J, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000; 118:A-655.
22. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330-1338.
23. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004; 53:1485-1493. Very interesting original paper evaluating the efficacy and safety of CDP-571 in patients with Crohn's disease.
24. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 1997; 11:1031-1035.
25. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003; 17:185-192.
26. Enbrel. Prescribing information. 2005. Thousand Oaks, CA: Immunex Corporation.
27. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088-1094.
28. D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001; 96:2564-2568.
29. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117:1278-1287.
30. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117:1271-1277.
31. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50:196-200.
32. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002; 35:149-150.
33. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002; 17:135-139.
34. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122:7-14.
35. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with mode rate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004; 20:1337-1346. Important study on efficacy and safety of treatment of Crohn's disease with CDP870.
36. Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized, placebo-controlled trial of Certolizumab pegol (CDP870) in active Crohn's Disease. Gastroenterology 2005; 129:807-818. Very important recent study regarding the use of CDP870 in Crohn's disease.
37. Sandborn W, Hanauer S, Lucas M, et al. Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-alpha monoclonal antibody Adalimumab (humira). Gastroenterology 2005; 128:A-112-A-112.
38. Hanauer S, Lukas M, Macintosh D, et al. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severly active Crohn's disease. Gastroenterology 2004; 127:332.
39. Sandborn W, Hanauer S, Loftus E Jr, et al. An open-label study of the human anti-TNF monoclonal antibody Adalimumab in subjects with prior loss of response or intolerance to Infliximab for Crohn's disease. Gastroenterology 2004; 126A-53-A-54.
40. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114:1133-1142.
41. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001; 120:1339-1346.
42. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002; 51:30-36.
43. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002; 16:1761-1770.
44. Van Deventer S, Volfova M, Flisiak R, et al. A phase 2 dose ranging, double-blind, placebo-controlled study of Alicaforsen enema in subjects with acute exacerbation of mild to moderate left sided ulcerative colitis. Gastroenterology 2005; 128:A-74.
45. Miner P, Nichols T, Schwartz H, et al. A phase 2 trial to assess the safety and efficacy of two dose formulations of Alicaforsen enema compared with 4g mesalamine enema for acute ulcerative colitis. Gastroenterology 2005; 2005:A-74.
46. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D 2004; 5:102-107.
47. Gordon FH, Hamilton Ml, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16:699-705.
48. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121:268-274.
49. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24-32.
50. Enns R, Colombel J, Feagan B, et al. Safety, tolerability and immunogenecity of natalizumab in a phase III study of active crohn's disease therapy (ENACT-1). Gastroenterology 2004; 126:A-462.
51. Lawrance I, Colombel J, Enns R, et al. Pharmacodynamic results from phase 3 Study Evaluating Natalizumab Therapy of Active Crohn's Disease (ENACT-1). Gastroenterology 2004; 126:A-211.
52. Sands B, Kozarek R, Spain hour J, et al. Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's Disease. Gastroenterology 2004; 126:A-463.
53. Sandborn W, Colombel J, Enns R, et al. A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of Antergen (Natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). Gastroenterology 2004; 127:332.
54. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-368.
55. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-381.
56. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369-374.
57. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005; 353:432-433.
58. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-2507. Very important recent study evaluating the efficacy and safety of humanized antibody to the α4β7 integrin in patients with ulcerative colitis.
59. Millennium Pharmaceuticals. Millennium Press Release: Millennium Announces Phase II Data for MLN02 in Crohn's Disease http://www.mlnm.com/media/ news/2002/2002%2D09%2D16%2D0.asp. [Accessed 8 May 2005].
60. Kasran A, Boon L, Wortel CH, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005; 22:111-122. Very important study focused solely on safety of new biologic agent in the treatment of Crohn's disease.
61. Plevy S, Salzberg B, Van Assche G, et al. A humanized anti-CD3 monoclonal antibody, Visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 2004; 126:A-75.
62. Rutgeerts P, Van Deventer S, Schreiber S. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther 2003; 17:1435-1450.
63. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383-389.
64. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119:1461-1472.
65. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473-1482.
66. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001; 49:42-46.
67. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64.
68. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16:399-406.
69. Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. Nat Med 2002; 8:567-573.
70. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069-2079. An interesting paper evaluating the use of anti-interleukin-12 antibody in Crohn's disease.
71. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-674.
72. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003; 18:65-75.
73. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003; 98:369-376.
74. Rutgeerts P, Reinisch W, Colombel JF, et al. Preliminary results of a phase I/II study of Huzaf, an Anti-INFg monoclonal antibody, in patients with moderate to severe active Crohn's disease. Gastroenterology 2002; 122:A-61.
75. Hommes D, Mikhajlova T, Stoinov S, et al. Fontolizumab (Huzaf), a humanized anti-INF-γ antibody, has a clinical activity and excellent tolerability in moderate to severe Crohn's disease. Gastroenterology 2004; 127:332.
76. Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342:1633-1637.
77. Sung C, Parry TJ, Riccobene TA, et al. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans. AAPS PharmSci 2002; 4:E8.
78. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003; 17:1355-1364.
79. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349:350-357.
80. Farrell RJ. Epidermal growth factor for ulcerative colitis. N Engl J Med 2003; 349:395-397.
81. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7:597-602.
82. Madsen SM, Schlichting P, Davidsen B, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001; 96:1807-1815.
83. Tilg H, Vogelsang H, Ludwiczek O, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003; 52:1728-1733.
84. Davidsen B, Munkholm P, Schlichting P, et al. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharmacol Ther 1995; 9:75-79.
85. Gasche C, Reinisch W, Vogelsang H, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995; 40:800-804.
86. Nikolaus S, Rutgeerts P, Fedorak RN, et al. Recombinant human interferon-beta (IFN-β-1a) induces remission and is well tolerated in moderately active ulcerative colitis (UC). Gastroenterology 2001; 120:A-454.
87. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360:1478-1480.
88. Dejaco C, Lichtenberger C, Miehsler W, et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion 2003; 68:63-70.
89. Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med 1999; 340:239-240.
90. Ito H, Takazoe M, Fukuda Y, et al. Effective treatment of active Crohn's disease with humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized placebo-controlled trial. Gastroenterology 2003; 124:A-25.
91. Travis S, Yap LM, Hawkey C, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005; 11:713-719. Very important study assessing efficacy and tolerability of new biologic agent of potential use in ulcerative colitis.